GNS Healthcare and Swedish Cancer Institute Launch Machine Learning Collaboration to Strengthen Delivery of Precision Medicine in Breast Cancer Care

By |

Causal Computer Models to Accelerate Work of Swedish Cancer Institute’s Molecular Tumor Board CAMBRIDGE, Mass. and SEATTLE, Sept. 13, 2017 /PRNewswire/ — Leading precision medicine company GNS Healthcare (GNS) and the Swedish Cancer Institute (SCI) today announced a machine learning collaboration to strengthen, accelerate, and potentially expand the delivery of precision medicine in breast cancer care. GNS will employ its breakthrough…

Read More

BioCentury highlights GNS-Alexion partnership

By |

Alexion rebuilding pipeline with big data deals   August 10, 2017 – Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is rebuilding its early stage pipeline with two new deals focused on driving rare disease discovery with big genomic data. The company partnered with Sema4 (New York, N.Y.) for genomic sequencing and licensed the Reverse…

Read More

GNS Healthcare Licenses REFS™ Causal Machine Learning and Simulation Platform to Alexion to Accelerate Discovery of New Treatments for Rare Diseases

By |

CAMBRIDGE, Mass. – August 10, 2017– GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to large and diverse data sets to better match drugs and other health interventions to individual patients, today announced that it has entered into a license arrangement with Alexion for the…

Read More